Electrophysiological studies suggest that a2-adrenoceptors profoundly affect monoaminergic neurotransmission by enhancing noradrenergic tone and serotonergic firing rates. Recent reports suggest that a2-antagonism may hasten and improve the response to antidepressant medications. To test this hypothesis, a randomized double-blind controlled trial was undertaken to determine if the combination of an a2-antagonist (yohimbine) with a selective serotonin reuptake agent (SSRI) (fluoxetine) results in more rapid onset of antidepressant action than an SSRI agent alone. In all, 50 subjects with a DSM-IV diagnosis of major depressive disorder confirmed by SCID interview were randomly assigned to receive either fluoxetine 20 mg plus placebo (F/P) or fluxetine 20 mg plus a titrated dose of yohimbine (F/Y). The yohimbine dose was titrated based on blood pressure changes over the treatment period, in a blind-preserving manner. Hamilton depression scale ratings (HDRS) and clinical global impression (CGI) ratings were obtained weekly over a period of 6 weeks. The rate of achieving categorical positive responses was significantly more rapid in the F/Y group compared to the F/P group using both the HDRS and the CGI scales as outcome measures in a survival analysis using a log-rank test (w 2 (1) ¼ 5.86, p ¼ 0.016 and w 2 (1) ¼ 5.29, p ¼ 0.021, respectively). At the last observed visit, 18 (69%) of the 26 F/Y subjects met the response criteria for CGI compared to 10 (42%) of 24 F/P subjects. Using the HDRS criteria, 17 (65%) of 26 F/Y subject vs 10 (42%) of 24 F/P subjects were responders. The addition of the a2-antagonist yohimbine to fluoxetine appears to hasten the antidepressant response. There is also a trend suggesting an increased percentage of responders to the combined treatment at the end of the 6-week trial.
INTRODUCTION
Enhancement of serotonergic function remains a dominant hypothesis regarding the proximal mechanism of selective serotonin reuptake inhibitor (SSRI) antidepressant action (Charney, 1998; Stahl, 1998) . Opposed to the serotonergic enhancing effects of the SSRIs, activation of several inhibitory receptors including the a2-adrenergic auto-and heteroreceptors are known to decrease 5-HT transmission.
a2-heteroreceptors located on presynaptic serotonergic terminals are tonically activated by endogenous noradrenaline (NE) (Mongeau et al, 1993; Feuerstein et al, 1993) , and release of serotonin is reduced when a2-adrenoreceptors are stimulated (Starke and Montel, 1973; Frankhuyzena and Mulder, 1980) . In addition, inhibitory a2-autoreceptors found on noradrenergic (NA) neurons in the locus coeruleus act to decrease firing of these neurons and thus decrease serotonergic transmission by reducing activation of stimulatory a1-receptors located on the 5-HT cell bodies in the raphe nucleus (Baraban and Aghajanian, 1980; Svensson et al, 1975) . Systemic administration of a2-antagonists has been shown to enhance serotonergic neurotransmission via direct inhibition of the a2-heteroceptors located on the serotonergic nerve terminals and indirect stimulation of a1-receptors via inhibition of a2-autoreceptors (Freedman and Aghajanian, 1984; Hopwood and Stamford, 2001; Haddjeri et al, 1996) .
Considering the inhibitory effects of the a2-adrenergic receptor on serotonergic function, it is hypothesized that the addition of an a2-antagonist to an SSRI agent may result in enhanced postsynaptic serotonergic transmission. Consistent with this hypothesis (Besson et al, 2000) , demonstrated that the coadministration of an SSRI and mirtazapine (an agent with a2-antagonist activity) shortens the delay in enhancing the tonic activation of the postsynaptic 5-HT 1A receptor. Based on the postulated role of enhanced serotonergic neurotransmission in the mechanism of SSRI antidepressant action, it is proposed that the addition of an a2-antagonist may produce a more rapid and/or enhanced antidepressant effect. Several preliminary clinical studies appear to support this premise by demonstrating effective augmentation of SSRI medications with a2-antagonist properties (Cappiello et al, 1995; Carpenter et al, 2002) , and reporting rapid rates of clinical response following combination treatments with SSRIs and a2-antagonists (Dam et al, 1998) . To further investigate this hypothesis, we investigated the effectiveness of combining yohimbine with the SSRI fluoxetine in hastening and improving the antidepressant response, using a randomized placebo-controlled double-blind study design.
PATIENTS AND METHODS

Subjects and Treatments
Subjects were recruited through newspaper advertisements indicating free treatment for major depression. A total of 50 medication-free outpatient subjects (not receiving an FDA approved antidepressant medication for at least 2 weeks prior to enrollment in the study), between the ages of 18-65 years, meeting the DSM-IV criteria for unipolar major depression without psychotic features participated in the study. All diagnoses were confirmed by a SCID interview (First et al, 2001) , and all subjects had initial 25-item Hamilton Rating Scale (Mazure et al, 1986 ) (HDRS) for Depression of 421. After completing a written informed consent process as approved by the Yale University and Connecticut VA institutional review boards, subjects were randomly assigned to receive one of two treatments: fluoxetine 20 mg QD plus placebo TID (n ¼ 24) or fluoxetine 20 mg QD plus yohimbine TID (n ¼ 26). Yohimbine (5.4 mg tabs; Watson Laboratories) and placebo were encapsulated identically. Yohimbine was titrated from one capsule TID up to a maximum of two tablets TID, in increments of one tablet per week based on maintenance of a diastolic blood pressure less than 90 mm/Hg and less than a 10 mm/Hg increase over the previous measurement. If a subject's blood pressure remained 4140/100 mm/Hg or HR 100 bpm the dose was cut by 5 mg; if it remained elevated after 1 week the subject was discharged from the study. Blood pressure was followed weekly by a third-party monitor who was not involved in the treatment or ratings of the subject. This monitor directly contacted the research pharmacist to determine medication dosing. To assure blinding of the subjects' clinicians and raters, the pharmacist yoked the number of placebo tablets administered to the number of yohimbine tablets administered to a randomly chosen yohimbine-treated subject. The introduction of additional psychotropic medications was not allowed during the 6-week assessment period.
Assessments
Subjects were seen weekly for assessments of mood and side effects. Rating assessments included the 25-item HDRS (Mazure et al, 1986) , Clinical Global Impressions Scale for severity (CGI) (Guy, 1986) , Hamilton Anxiety Rating Scale (HARS) (Hamilton, 1969) , and the Arizona Sexual Experience scale (ASEX) (this was performed on the last 27 subjects, as it was added later in the study) (McGahuey et al, 2000) .
Statistical Analysis
The main outcome of interest was time to antidepressant response. This was examined using a survival analysis, with the 'survival time' defined as the time when a subject met the a priori determined response criteria. The criterion for HDRS was defined as a score of p10, reflecting a measure consistent with remission. For CGI, the criterion was defined as a score of p2 (borderline ill, no functional impairment). Subjects were considered responders at the time they met response criteria for the first time. In the case of dropout before becoming responder, the subject was censored after the last time-point that data was collected. The survival analyses were performed using PROC LIFET-EST in SAS 8.2. w 2 tests were used to compare percent responders at end point based on the HDRS and on the CGI criteria explained above. End point data was analyzed using the last observation carried forward method. Change in HDRS ratings was also analyzed using a mixed models approach (in SAS PROC MIXED) with treatment, time, and treatment by time effects. Change in CGI ratings were also analyzed using a GEE cumulative-logit model for ordinal data (in SAS PROC GENMOD) with treatment, time, and treatment by time effects.
As secondary analyses, HARS and ASEX (in a subset of subjects) ratings were analyzed using mixed models with treatment, time, treatment by time effects, and baseline as covariates. The data were checked for normality by the Kolmogorov-Smirnov tests. The models were fitted in SAS PROC MIXED with AR(1) variance-covariance structure. All statistical tests were two-sided and performed at 0.05 significance level.
RESULTS
The demographics and clinical characteristics are presented in Table 1 . There was no significant difference between the two groups of subjects in terms of baseline severity of depression or anxiety, duration of current episode, number Addition of yohimbine to fluoxetine G Sanacora et al of previous episodes, age, weight, sexual dysfunction, or gender composition. The combined sample was composed of 38% males and 62% females with mean (7SD) age of 43.979.8 years. The mean baseline HDRS was 3076. The majority of subjects (70%) had prior major depressive episodes, and 48% of the sample had received a previous antidepressant trial at some point. Only four of the subjects had a history of psychiatric hospitalization, and four subjects had a history of suicide attempt or gesture. The average duration of current episode was 58740 weeks. Seven subjects from the F/Y group (27%) discontinued the study before the end of week 6, due to emergent hypertension (4), urinary retention (1), and loss to followup (2). Three of the F/Y subjects discontinued the study after achieving response criteria. Five subjects from the F/P group (21%) discontinued prior to the end of week 6, due to worsening of depressive symptoms (2), rash (1), acute onset of Lyme disease (1), and loss to follow-up (1). None of the F/P subjects achieved response criteria prior to discontinuing the study. In all, 15 of the 19 subjects in the F/Y group who completed the study tolerated the titration up to 10.8 mg TID, with the mean dose being 27.674.8 mg at the end of the trial. Yohimbine dose increases were limited in four subjects due to increased blood pressure (2), tremulousness (1), and lightheadedness (1).
Antidepressant Response
The subjects in the F/Y group more rapidly met the predetermined HDRS response criterion (final HDRS 10) than did the F/P group using a Log rank test [w (Table 2) and CGI scores were numerically lower in the F/Y group at every time point in the study, there was not a significant time by treatment interaction for the change from baseline in either measure [F(5,197 (Table 3) , and there was a significant time effect (F(6, 44.4) ¼ 10.73, po0.0001), indicating that there was significant improvement with time for both the groups. 
Sexual Dysfunction Results
Since the ASEX was added to the rating battery at a later time, we were only able to collect the ASEX ratings on 27 subjects (15 F/Y and 12 F/P) ( 
DISCUSSION
The main findings of this study are consistent with the hypothesis postulating that coadministration of a2-antagonists can hasten the antidepressant effects of SSRI medications. Subjects receiving fluoxetine in combination with yohimbine appear to respond more rapidly than those receiving fluoxetine alone do, showing earlier categorical responses on both HAM-D and CGI scales. The results are similar to those of a previous study that demonstrated a statistically significant greater reduction of depressive symptoms shortly after the initiation of treatment with fluoxetine combined with mianserin (an agent with a2-antagonist properties) compared to fluoxetine alone (Dam et al, 1998) . However, unlike the previous study that demonstrated significantly greater improvement at the end of the first week of treatment with mianserin, we did not see major differences between the two conditions until the end of the third week of treatment. This raises the possibility of a minimal yohimbine dose threshold that is reached only after a 3-week period of dose escalation. However, it may also suggest that the enhanced antidepressant effect is not fully accounted for by the acute effects of a2-antagonism. Interestingly, two recent reviews examining the onset time of antidepressant action for mirtazapine, a compound with antagonist properties at both a2-adrenergic auto-and heteroreceptors, suggest that it may also be associated with an earlier onset of response (Quitkin et al, 2001; Nierenberg, 2001) . The end point analyses also suggest a trend for combined therapy subjects reaching response criteria in greater numbers at the 6-week period, supporting the idea that a2-antagonists lead to improved antidepressant efficacy. This is consistent with a study by (Carpenter et al, 2002) , in which treatment refractory depressed subjects, most of whom were receiving SSRI medications, demonstrated a categorical response rate of 64% after 4-weeks of mirtazapine augmentation compared to a 20% categorical response rate with placebo addition.
The findings of the study are tempered, however, by the fact that we did not demonstrate a significant main effect of treatment or a treatment by time interaction in the mixed models analyses examining mean changes in HDRS and CGI scores. This may be accounted for by the fact that the primary parameter of interest, time to response, is calculated individually for each patient in the survival analysis technique rather than from group means, thus providing a more accurate measure of the parameter (Thase, 2001) . The fact that the dropout mechanism was informative and different in the two groups (three of the F/Y subjects dropped out after obtaining a response, while none of the F/P dropouts achieved a response prior to termination) may also contribute to this apparent contradiction. However, the discrepancy could also be the result of an artifact caused by the choice of a defined response criterion (HDRS p10) and a baseline HDRS that is numerically but not statistically lower in the F/Y group. In general, our results are consistent with the previously proposed hypothesis that concomitant administration of a2-antagonists and SSRI medications may lead to more rapid rates of antidepressant effects by shortening the delay in obtaining tonic activation of the postsynaptic 5-HT 1A receptors (Besson et al, 2000) . It is important to state, however, that yohimbine is not a highly selective a2 antagonist since it also binds to 5-HT2, and dopamine D2 receptors (Krystal et al, 1992) . Beyond increasing postsynaptic serotonergic activation, the effect may also be related to enhanced activation of the NA system via blockade of the inhibitory a2-receptor. Thus, the dual activation of the serotonergic and NA systems simultaneously may contribute to findings. It does not appear likely, however, that increasing NA transmission alone is responsible for the effect since a previous study, combining yohimbine with the NA selective agent desipramine, failed to show any benefit over desipramine alone in a sample of treatment refractory subjects (Charney et al, 1986) . Lastly, an additional caveat in interpreting the findings of this study is drawn from the fact that serum concentrations of fluoxetine were not measured in the subjects. Therefore, we cannot rule out the possibility that yohimbine is having a pharmacokinetic effect that results in altered metabolism of fluoxetine. However, this does not seem to be a likely explanation considering the lack of clear evidence to support a significant dose-response effect with fluoxetine at doses greater than 20 mg in the treatment of major depression.
Interestingly, we did not see any worsening of anxiety symptoms in this study. a2-antagonists have been shown to induce panic attacks in susceptible individuals (Krystal et al, 1992) ; however, we did not see any significant increase in panic attacks or anxiety ratings on the HARS. In fact, there was a significant improvement in HARS over the 6-week course that appeared independent of whether or not yohimbine was administered. Yohimbine has also been reported to ameliorate antidepressant-associated sexual dysfunction (Hollander and McCarley, 1992; Price and Grunhaus, 1990) , although a recent placebo-controlled trial did not support this claim (Michelson et al, 2002) . Our preliminary findings from this study do not show a clear effect of yohimbine on sexual function but suggest a possible trend for improved function in the later weeks of the trial in the subjects randomized to combination therapy.
In conclusion, the addition of the a2-antagonist yohimbine appears to hasten and possibly improve the antidepressant response rates to the SSRI agent fluoxetine. This finding is consistent with the hypothesis that concomitant administration of a2-antagonists and SSRI medications may lead to more rapid rates of antidepressant effects. While the findings are of significant interest in relationship to our understanding of the underlying neurobiology associated with antidepressant action, they do not clearly support the clinical use of yohimbine as a clinical agent. Several of the subjects in this study developed hypertension with the combination and we were unable to clearly show any benefit of the combination at the end of the 6-week trial. Additional studies concerning the clinical usefulness of the combination are required.
